Why the study?
Does intensive treatment of SBP to less than 120 mmHg reduce all-cause mortality or CKD compared to standard treatment (<140 mmHg) in hypertensive patients aged 50-90 without diabetes or CKD?
Population
12,743 hypertensive patients aged 50-90 without diabetes or chronic kidney disease from the US SPRINT trial…
Comparison
Intensive treatment of systolic blood pressure… vs Standard treatment of systolic blood pressure to…
Design
Cohort
Follow-up
up to 5 years (enrolled 2010-2013, followed up to 2015)
Authors
Loading...
Conflicting mortality signals across cohorts advise against routine intensive SBP targets; leaves open net effects on CKD and survival in real-world hypertensives.
Does intensive treatment of SBP to less than 120 mmHg reduce all-cause mortality or CKD compared to standard treatment (<140 mmHg) in hypertensive patients aged 50-90 without diabetes or CKD?
Gitsels et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: